A practical reference on research peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-17 and is reviewed periodically as new material appears.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
These drugs have been derived from NSAIDs. The cyclooxygenase enzyme inhibited by NSAIDs was discovered to have at least two different versions: COX-1 and COX-2. Research suggested most of the adverse effects of NSAdiated by blocking the COX-1 (constitutive) enzyme, with the analgesic effects being mediated by the COX-2 (inducible) enzyme. Thus, the COX-2 inhibitors were developed to inhibit only the COX-2 enzyme (traditional NSAIDs block both versions in general). These drugs (e.g., rofecoxib, celecoxib, and etoricoxib) are equally effective analgesics when compared with NSAIDs, but cause less gastrointestinal hemorrhage in particular. After widespread adoption of the COX-2 inhibitors, it was discovered that most of the drugs in this class increase the risk of cardiovascular events by 40% on average. This led to the withdrawal of rofecoxib and valdecoxib, and warnings on others. Etoricoxib seems relatively safe, with the risk of thrombotic events similar to that of non-coxib NSAID diclofenac.
=== Medical === Indigenous healers in Africa use different parts of the locust bean tree for health benefits. In a survey conducted on healers in Togo, Parkia biglobosa was one of the highest cited plants used for treating hypertension. The tree was also one of two plants "listed as having real wound-healing properties in South-Western Nigeria, influencing the proliferation of dermal fibroblasts significantly." In a similar survey conducted in Guinea relating to their use of antimalarial plants, Parkia biglobosa was cited among those most often successfully used. In an analysis on the antibacterial properties of the plant, another study found that "these properties compare favourably with those of streptomycin, making it a potential source of compounds used in the management of bacterial infections."
Nidanas 1, 2 and 3 which cast beings downward into the whirl of transmigration Nidanas 4 to 7 represent what undergoes transmigration, "the aspects of the person undergoing phenomenal life" (Wayman). Nidanas 8, 9, 10 produce new karma Nidanas 11 and 12 are the fruits or results of karma produced previously According to Gombrich, the "contorted" three lives interpretation is rendered unnecessary by the analysis provided by Jurewicz and other scholars which show that the 12 link chain is a composite list.
Sources: en.wikipedia.org
Conversely, the change may allow the cell to continue functioning albeit differently, and the mutation can be passed on to the organism's offspring. If this change does not result in any significant physical disadvantage to the offspring, the possibility exists that this mutation will persist within the population. The possibility also exists that the change in function becomes advantageous. In either case, while being subjected to the processes of natural selection, the point mutation has been accepted into the genetic pool. The 20 amino acids translated by the genetic code vary greatly by the physical and chemical properties of their side chains. However, these amino acids can be categorised into groups with similar physicochemical properties. Substituting an amino acid with another from the same category is more likely to have a smaller impact on the structure and function of a protein than replacement with an amino acid from a different category. Consequently, acceptance of point mutations depends heavily on the amino acid being replaced in the mutation, and the replacement amino acid. The PAM matrices are a mathematical tool that account for these varying rates of acceptance when evaluating the similarity of proteins during alignment.
Around this time, a coachbuilder company called PT. Marvia Graha Motor (owned by Marvy Apandi, the executive director of Indomobil Group) built around 50 units replica of Porsche 911 (964) based on MR90 hatchbacks. While retaining the original 1.4-litre engine, 5-speed manual gearbox, suspension and dashboard (later models has 964 dashboard replica), the body was made from fiberglass by using the 964 production tools from VW Group. At that time Indomobil had a trial by assembling two Porsche 964 and planned to build Porsche and Audi in Indonesia to compete with BMW and Mercedes-Benz. The plan was terminated because the production quality was below VW Group's standard.
== E == Setsuro Ebashi (1922–2006). Japanese biochemist at the University of Tokyo who discovered troponin. Richard H. Ebright (b. 1959). American molecular biologist at Rutgers University, known for work on protein-DNA interaction, aspects of transcription, and antibacterial drug discovery. John Tileston Edsall (1902–2002). American protein chemist at Harvard, very influential in protein research, and author (with Edwin Cohn) of Proteins, Amino Acids and Peptides. Member Natl. Acad. Sci. USA. Konstantin Efetov (b. 1958). Ukrainian biochemist at Crimea State Medical University, known for work in molecular immunology, evolutionary biology, and biosystematics. Gertrude B. Elion (1918–1999). American biochemist and pharmacologist at Duke University, known for using rational drug design for the discovery of new drugs. Nobel Prize in Physiology or Medicine (1988). Conrad Elvehjem (1901–1962). American biochemist and nutritionist at the University of Wisconsin, known for identifying two vitamins, nicotinic acid, and nicotinamide. Gladys Anderson Emerson (1903–1984). American historian, biochemist and nutritionist at UCLA, the first to isolate Vitamin E in a pure form. Akira Endo (1933–2024). Japanese biochemist at the Tokyo University of Agriculture and Technology. His research into the relationship between fungi and cholesterol biosynthesis led to the development of statin drugs. Foreign associate Natl. Acad. Sci. USA. Donald Engelman (b. 1941). American biochemist at Yale, involved in the creation of new cancer drugs and treatments. Member Natl. Acad. Sci.
=== Foe === A foe is a unit of energy equal to 1044 joules (≈9.478×1040 BTU) that was invented by physicist Gerry Brown of Stony Brook University. To measure the staggeringly immense amount of energy produced by a supernova, specialists occasionally use the "foe", an acronym derived from the phrase [ten to the power of] fifty-one ergs, or 1051 ergs. This unit of measure is convenient because a supernova typically releases about one foe of observable energy in a very short period of time (which can be measured in seconds).
Sources: en.wikipedia.org
During the 2025 legislative session, Moore introduced the Expungement Reform Act, a bill that would expand criminal record expungement options for violations of parole and probation. He also expressed support for state efforts aimed at "supporting an elevating our men and boys" by removing barriers that keep men out of the workforce, including those returning from incarceration. In April 2025, Moore signed the Expungement Reform Act and the Second Look Act—which allows people incarcerated for at least 20 years for crimes they committed between the ages of 18 and 25 to petition for a reduced sentence—into law. In September 2025, Moore announced that his administration would close the Maryland Correctional Institution - Jessup and transfer prisoners held there to other prisons in the state, saying that the facility would've needed $200 million in renovations to continue operations. In January 2026, he proposed a pause on funding for the construction of the Baltimore Therapeutic Treatment Center, a new jail in Baltimore designed for people who have substance use issues and are facing criminal charges. In May 2026, Moore signed into law the Youth Charging Reform Act, which removes first-degree assault and several handgun offenses from the list of offenses that result in minors being automatically charged as adults.
=== Former hospitals === Former UPMC hospitals include UPMC Sunbury in Sunbury, Pennsylvania (2017–2020) which was closed and services integrated into other nearby facilities; UPMC Beacon Hospital in Dublin, Ireland (2009 to 2014) which was acquired by Irish businessman Denis O'Brien; UPMC Braddock in Braddock, Pennsylvania (1996 to 2010) which was closed; UPMC South Side hospital in Pittsburgh (1996 to 2009) which was merged with UPMC Mercy and converted into UPMC Mercy South Side Outpatient Center; UPMC Lee Regional in Johnstown, Pennsylvania (1998 to 2005) which was sold to Conemaugh Health System; and UPMC Beaver Valley in Aliquippa, Pennsylvania (1996 to 2001) which was transferred back to its community board and subsequently closed. UPMC Pinnacle Lancaster, formerly St. Joseph's hospital in Lancaster, Pennsylvania, closed on February 28, 2019, and its services were consolidated into UPMC Pinnacle Lititz.
In the eocyte hypothesis linking the closest known archaeal relatives of eukaryotes (achaean eocytes), the organism at the root of the eocytes lineage may have been a ribocyte from the RNA-world. For cellular DNA and DNA processing systems, an "out of virus" scenario has been proposed. In this model, DNA as the main genetic information material may have first evolved in viruses and was later transferred to ribocytes twice: once transforming them into bacteria and once transforming them into archaea. Similarly in viral eukaryogenesis, a hypothesis theorizing that eukaryotes evolved from a DNA virus, ribocytes may have been an ancient host for a DNA virus. Because ribocytes used RNA to store their genetic information, viruses may initially have used DNA as a way to resist RNA-degrading enzymes present in the host ribocells. The introduction of a DNA-based system may have been as significant for protocells as later additions of chloroplasts or mitochondria through endosymbiosis in evolving eukaryotic cells. In this hypothesis, bacteria, archaea, and eukaryotes each obtained their DNA informational system from a different virus. In the reduction hypothesis, where giant viruses evolved from primordial cells that became parasitic, viruses might have evolved after FUCA but before LUCA.
== Further reading == "Soutien-gorge de sport", in Thierry Adam, Gynécologie du sport (in French). Springer 2012, pp. 305–309. "Facteurs de l'évolution morphologique du sein après arrêt du port du soutien-gorge : étude ouverte préliminaire longitudinale chez 50 volontaires. Olivier Roussel; Jean-Denis Rouillon; Université de Franche-Comté. Faculté de médecine et de pharmacie" (in French). Thèse d'exercice : Médecine : Besançon : 2009.
== Bone structure == The skeleton is a large organ that is formed and degraded throughout life in the air-breathing vertebrates. The skeleton, often referred to as the skeletal system, is important both as a supporting structure and for maintenance of calcium, phosphate, and acid–base status in the whole organism. The functional part of bone, the bone matrix, is entirely extracellular. The bone matrix consists of protein and mineral. The protein forms the organic matrix. It is synthesized and then the mineral is added. The vast majority of the organic matrix is collagen, which provides tensile strength. The matrix is mineralized by deposition of hydroxyapatite (alternative name, hydroxylapatite). This mineral is hard, and provides compressive strength. Thus, the collagen and mineral together are a composite material with excellent tensile and compressive strength, which can bend under a strain and recover its shape without damage. This is called elastic deformation. Forces that exceed the capacity of bone to behave elastically may cause failure, typically bone fractures.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.